Progress in Pediatric Cardiology
Volume 27, Issue 1 , Pages 25-33 , December 2009

Pulmonary arterial hypertension associated with congenital heart disease

  • Tom Kulik

      Affiliations

    • Department of Cardiology, Children's Hospital Boston, 300 Longwood Ave, Boston, MA, USA
    • ,
  • Mary Mullen

      Affiliations

    • Department of Cardiology, Children's Hospital Boston, 300 Longwood Ave, Boston, MA, USA
    • ,
  • Ian Adatia

      Affiliations

    • Pediatric Pulmonary Hypertension Clinic, Division of Pediatric Cardiology, Stollery Children's Hospital, University of Alberta, Edmonton, Canada
    • Corresponding Author InformationCorresponding author. Room 3A1.44, Walter C Mackenzie Health Sciences Center, 8440 112 St, Edmonton, AB, Canada T6G 3T7. Tel.: +1 780 407 3642.

References 

  1. Adatia I. Pulmonary vascular disease. In:  Freedom RM,  Yoo S-J,  Mikailian H,  Williams WG editor. The natural and modified history of congenital heart disease. New York: Futura; 2004;p. 518
  2. Tefuarini N, Hawker R, Vince J, Sleigh A, Williams GM. Surgical programme at Royal Alexandria Hospital, Sydney, for Papua New Guinea children with congenital heart disease, 1978–1994. J Paediatr Child Health. 2002;38:178–182
  3. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation. Oct 21 2008;118(17):1758–1766
  4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. Jun 16 2004;43(12 Suppl S):5S–12S
  5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54
  6. Lee S-D, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927–934
  7. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004 Sep;24(3):371–374
  8. Harrison RE, Berger R, Haworth SG, et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation. Feb 1 2005;111(4):435–441
  9. Wood P. The eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ (Clinical research ed.). 1958;2:701–709
  10. Shepherd JT, Semler HJ, Helmholz HF, Wood EH. Effects of infusion of acetylcholine on pulmonary vascular resistance in patients with pulmonary hypertension and congenital heart disease. Circulation. 1959;20:381–390
  11. Swan HJC, Burchell HB, Wood EH. Effect of oxygen on pulmonary vascular resistance in patients with pulmonary hypertension associated with atrial septal defect. Circulation. 1959;20:66–73
  12. Vogel JH, Grover RF, Jamieson G, Blount SG. Long-term physiologic observations in patients with ventricular septal defect and increased pulmonary vascular resistance (with 2 color plates). Adv Cardiol. 1974;11(00):108–122
  13. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. part 1 Circulation. 1993;88:2128–2138
  14. Neutze JM, Ishikawa T, Clarkson PM, Calder AL, Barratt-Boyes BG, Kerr AR. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol. Feb 1 1989;63(5):327–331
  15. Bush A, Busst C, Booth K, Knight WB, Shinebourne EA. Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?. Circulation. 1986;74(1):135–144
  16. Brammell HL, Vogel JHK, Pryor R, Blount SG. The Eisenmenger syndrome a clinical and physiological reappraisal. Am J Cardiol. 1971;28:679–692
  17. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J. 1986;55:385–390
  18. Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. Sep 2004;25(18):1651–1656
  19. Auld PAM, Gibbons JE, McGregor M. Vasomotor tone in the pulmonary vascular bed in patients with left to right shunts. Br Heart J. 1963;25:257–261
  20. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1958;20:557–570
  21. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. Circulation. 1958;28:533–547
  22. Rabinovitch M, Haworth S, Castaneda A, Nadas A, Reid L. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation. 1978;58:1107–1122
  23. Haworth SG. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol. Jul 1987;152(3):157–168
  24. Haworth SG, Hislop AA. Pulmonary vascular development: normal values of peripheral vascular structure. Am J Cardiol. Sep 1 1983;52(5):578–583
  25. Eisenmenger V. Die angeborenes Defekt der Kammerschiedewand des Herzen. Z Klin Med Suppl. 1897;32:1–28
  26. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ (Clinical research ed.). 1958;2:755–762
  27. Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol. 1995;25(7):1652–1664
  28. Budts W, Pelt NV, Gillyns H, Gewillig M, Werf FVd, Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart (British Cardiac Society). 2001;86:553–558
  29. Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation. Apr 1984;69(4):655–667
  30. Hoffman J, Rudolph A, Heymann M. Pulmonary vascular disease with congenital heart lesions; pathological features and causes. Circulation. 1981;64:873–877
  31. Epting CJ, Wolfe RR, Abman SH, Deutsch GH, Ivy D. Reversal of pulmonary hypertension associated with plexiform lesions in congenital heart disease; a case report. Pediatr Cardiol. 2002;23:182–185
  32. Weidman W, Blount S, DuShane J, Gersony W, Hayes C, Nadas A. Clinical course in ventricular septal defect. Circulation. 1977;56(Suppl l):I-56-69
  33. Dexter L. Atrial septal defect. Br Heart J. Apr 1956;18(2):209–225
  34. Craig RJ, Selzer A. Natural history and prognosis of atrial septal defect. Circulation. May 1968;37(5):805–815
  35. Besterman E. Atrial septal defect with pulmonary hypertension. Br Heart J. 1961;23:587–598
  36. Goetschmann S, Dibernardo S, Steinmann H, Pavlovic M, Sekarski N, Pfammatter JP. Frequency of severe pulmonary hypertension complicating “isolated” atrial septal defect in infancy. Am J Cardiol. Aug 1 2008;102(3):340–342
  37. Haworth SG. Pulmonary vascular disease in secundum atrial septal defect in childhood. Am J Cardiol. 1982;51:265–272
  38. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease-long term follow up and prediction of outcome after surgical correction. Circulation. 1987;76(5):1037–1042
  39. Cherian G, Uthaman CB, Durairaj M, et al. Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients. Am Heart J. 1983;105:952–957
  40. Yamaki S, Horiuchi T, Miura M, Suzuki Y, Ishizawa E, Takahashi T. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension. Chest. 1986;89(5):694–698
  41. Bull C, Deanfield J, de Leval M, Stark J, Taylor JF, Macartney FJ. Correction of isolated secundum atrial septal defect in infancy. Arch Dis Child. Oct 1981;56(10):784–786
  42. Manning PB, Mayer JE, Sanders SP, et al. Unique features and prognosis of primum ASD presenting in the first year of life. Circulation. Nov 1994;90(5 Pt 2):II30–II35
  43. Yeager SB, Freed MD, Keane JF, Norwood WI, Castaneda AR. Primary surgical closure of ventricular septal defect in the first year of life: results in 128 infants. J Am Coll Cardiol. May 1984;3(5):1269–1276
  44. Clarkson PM, Frye RL, DuShane JW, Burchell HB, Wood EH, Weidman WH. Prognosis for patients with ventricular septal defect and severe pulmonary vascular disease. Circulation. 1968;38:129–135
  45. Friedli B, Kidd BL, Mustard W, Keith J. Ventricular septal defect with increased pulmonary vascular resistance. Am J Cardiol. 1974;33:403–409
  46. Cartmill T, DuShane J, McGoon D, Kirklin J. Results of repair of ventricular septal defect. J Thorac Cardiovasc Surg. 1966;52(4):486–501
  47. Castañeda AR, Zamora R, Nicoloff DM, Moller JH, Hunt CE, Lucas RV. High-pressure, high resistance ventricular septal defect. Ann Thorac Surg. 1971;12:29–36
  48. Sigmann JM, Perry BL, Gehrendt DM, Stern AM, Kirsh MM, Sloan HE. Ventricular septal defect: results after repair in infancy. Am J Cardiol. Jan 1977;39(1):66–71
  49. Hallidie-Smith KA, Hollman A, Cleland WP, Bentall HH, Goodwin JF. Effects of surgical closure of ventricular septal defects upon pulmonary vascular disease. Br Heart J. Mar 1969;31(2):246–260
  50. Kidd L, Rose V, Collins G, Keith J. The hemodynamics in ventricular septal defect in childhood. Am Heart J. Dec 1965;70(6):732–738
  51. Keith J. Ventricular septal defect. In:  Keith J,  Vlad P,  Rowe RD editor. Heart disease in infancy and childhood. New York: Macmillan Publishing Co; 1978;p. 320–379
  52. Moller JH, Patton C, Varco RL, Lillehei CW. Late results (30 to 35) years after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol. 1991;68:1491–1497
  53. Lueker RD, Vogel JH, Blount SG. Cardiovascular abnormalities following surgery for left-to-right shunts. Observations in atrial septal defects, ventricular septal defects, and patent ductus arteriosus. Circulation. Dec 1969;40(6):785–801
  54. Wallgren CG, Boccanelli A, Zetterqvist P, Bjork VO. Late results after surgical closure of ventricular septal defect in children. Scand J Thorac Cardiovasc Surg. 1980;14(2):145–151
  55. Ikawa S, Shimazaki Y, Nakano S, Kobayashi J, Matsuda H, Kawashima Y. Pulmonary vascular resistance during exercise late after repair of large ventricular septal defects. Relation to age at the time of repair. J Thorac Cardiovasc Surg. Jun 1995;109(6):1218–1224
  56. Hallidie-Smith KA, Wilson RS, Hart A, Zeidifard E. Functional status of patients with large ventricular septal defect and pulmonary vascular disease 6 to 16years after surgical closure of their defect in childhood. Br Heart J. Oct 1977;39(10):1093–1101
  57. Kulik TJ, Bass JL, Fuhrman BP, Moller JH, Lock JE. Exercise induced pulmonary vasoconstriction. Br Heart J. Jul 1983;50(1):59–64
  58. Maron BJ, Redwood DR, Hirshfeld JW, Goldstein RE, Morrow AG, Epstein SE. Postoperative assessment of patients with ventricular septal defect and pulmonary hypertension. Response to intense upright exercise. Circulation. Oct 1973;48(4):864–874
  59. Kannan BR, Sivasankaran S, Tharakan JA, et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J. Mar–Apr 2003;55(2):161–166
  60. Haworth SG. Pulmonary vascular disease in different types of congenital heart disease. Br Heart J. 1984;52:557–571
  61. Clarkson PM, Neutze JM, Wardill JC, Barratt-Boyes BG. The pulmonary vascular bed in patients with complete transposition of the great arteries. Circulation. Mar 1976;53(3):539–543
  62. Lakier JB, Stanger P, Heymann MA, Hoffma NJ, Rudolph AM. Early onset of pulmonary vascular obstruction in patients with aortopulmonary transposition and intact ventricular septum. Circulation. May 1975;51(5):875–880
  63. Keane JF, Ellison RC, Rudd M, Nadas AS. Pulmonary blood flow and left ventricular volumes in transposition of the great arteries and intact ventricular septum. Br Heart J. May 1973;35(5):521–526
  64. Newfeld EA, Paul MH, Muster AJ, Idriss FS. Pulmonary vascular disease in transposition of the great vessels and intact ventricular septum. Circulation. Mar 1979;59(3):525–530
  65. Sreeram N, Petros A, Peart I, Arnold R. Progressive pulmonary hypertension after the arterial switch procedure. Am J Cardiol. 1994;73:620–621
  66. Rivenes SM, Grifka RG, Feltes TF. Development of advanced pulmonary vascular disease in D-transposition of the great arteries after the neonatal arterial switch operation. Tex Heart Inst J. 1998;25(3):201–205
  67. Kumar A, Taylor G, Sandor G, Patterson M. Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum. Br Heart J. 1993;69:442–445
  68. Maeno Y, Hornberger LK, Kamenir SA, Sinclair B, Smallhorn JF. Prenatal features of restrictive foramen ovale and ductal constriction in D-transposition of the great arteries. Circulation. 1997;(I–129):724A
  69. Soongswang J, Adatia I, Newman C, Smallhorn JF, Williams WG, Freedom RM. Mortality in potential arterial switch candidates with transposition of the great arteries. J Am Coll Cardiol. 1998;32:753–757
  70. Rudolph A. Congenital diseases of the heart: clinical–physiological considerations. In: Armonk, New York: Futura; 2001;p. 703
  71. Juaneda E, Haworth SG. Pulmonary vascular disease in children with truncus arteriosus. Am J Cardiol. Dec 1 1984;54(10):1314–1320
  72. Mair DD, Ritter DG, Davis GD, Wallace RB, Danielson GK, McGoon DC. Selection of patients with truncus arteriosus for surgical correction. Circulation. 1974;49:144–151
  73. Agarwala B, Waldman JD, Sand M, Loe WA, Ruschhaupt DG. Aortic origin of the RPA: immediate resolution of severe pulmonary artery hypertension by surgical repair. Pediatr Cardiol. 1994;15:41–44
  74. Freedom RM, Yoo S-J, Coles JG. Atrioventricular septal defect. In:  Freedom RM,  Yoo S-J,  Mikailian H,  Williams WG editor. The natural and modified history of congenital heart disease. New York: Futura; 2004;
  75. Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. N Engl J Med. 1982;307:1170–1173
  76. Marino B. Patterns of congenital heart disease and associated cardiac anomalies in children with Down syndrome. In:  Marino B,  Pueschel SM editor. Heart disease in persons with Down syndrome. Baltimore, Maryland: Paul H Brookes Publishing Co; 1996;p. 133–140
  77. Vogel JH, McNamara DG, Blount SG. Role of hypoxia in determining pulmonary vascular resistance in infants with ventricular septal defects. Am J Cardiol. Sep 1967;20(3):346–349
  78. Chen QH, Wang XQ, Qi SG. Cross-sectional study of congenital heart disease among Tibetan children aged from 4 to 18years at different altitudes in Qinghai Province. Chin Med J (Engl). Dec 20 2008;121(24):2469–2472
  79. Miao CY, Zuberbuhler JS, Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol. Jul 1988;12(1):224–228
  80. Penaloza D, Arias-Stella J, Sime F, Recavarren S, Marticorena E. The heart and pulmonary circulation in children at high altitudes: physiological, anatomical, and clinical observations. Pediatrics. Oct 1964;34:568–582
  81. Niermeyer S. Cardiopulmonary transition in the high altitude infant. High Alt Med Biol. Summer 2003;4(2):225–239
  82. Sime F, Banchero N, Peñaloza D, Gamboa R, Cruz J, Marticorena E. Pulmonary hypertension in children born and living at high altitudes. Am J Cardiol. 1963;11:143–149
  83. Williams D. Adaptation and acclimatisation in humans and animals at high altitude. Thorax. 1994;49:S9–S13
  84. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes:helthyhighlanders and chronic moutain sickness. Circulation. 2007;115:1132–1146
  85. Langille BL. Arterial remodeling: relation to hemodynamics. Can J Physiol Pharmacol. Jul 1996;74(7):834–841
  86. Li C, Xu Q. Mechanical stress-initiated signal transduction in vascular smooth muscle cells in vitro and in vivo. Cell Signal. May 2007;19(5):881–891
  87. Reddy VM, Meyrick B, Wong J, et al. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation. Aug 1 1995;92(3):606–613
  88. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM. Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. Jul 2003;285(1):L209–L221
  89. Mata-Greenwood E, Meyrick B, Soifer SJ, Fineman JR, Black SM. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. Jul 2003;285(1):L222–L231
  90. Black SM, Bekker JM, Johengen MJ, Parry AJ, Soifer SJ, Fineman JR. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res. Jan 2000;47(1):97–106
  91. Wedgwood S, Devol JM, Grobe A, et al. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res. Jan 2007;61(1):32–36
  92. Botney MD. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med. Feb 1999;159(2):361–364
  93. Rabinovitch M, Konstam MA, Gamble WJ, et al. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res. Apr 1983;52(4):432–441
  94. O'Blenes SB, Fischer S, McIntyre B, Keshavjee S, Rabinovitch M. Hemodynamic unloading leads to regression of pulmonary vascular disease. J Thorac Cardiovasc Surg. 2001;121:279–289
  95. Adatia I, Barrow S, Stratton P, Ritter J, Haworth S. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J. 1994;72:452–456
  96. Adatia I, Barrow SE, Stratton P, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation. 1993;88:2117–2122
  97. Stewart D, Levy R, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med. 1991;114:464–469
  98. Komai H, Adatia I, Elliott MJ, Leval MRd, Haworth SG. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 1993;106:473–478
  99. Gorenflo M, Gross P, Bodey A, et al. Plasma endothelin-1 in patients with left-to-right shunt. Am Heart J. 1995;130:537–542
  100. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. Dec 1991;84(6):2280–2285
  101. Adatia I, Haworth SG. Circulating endothelin in children with congenital heart disease. Br Heart J. 1993;69:233–236
  102. Yamamoto K, Ikeda U, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Endothellin production in pulmonary circulation of patients with mitral stenosis. Circulation. 1994;89:2093–2098
  103. Feinstein JA. Evaluation, risk stratification, and management of pulmonary hypertension in patients with congenital heart disease. Semin. Thorac. Cardiovasc. Surg. 2009;12:106–111
  104. Jones ODH, Shore DF, Rigby ML, et al. The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children. Circulation. 1981;64(Suppl II):II-134-II-9
  105. Hopkins RA, Bull C, Haworth SG, Leval MRd, Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg. 1991;5:628–634
  106. Balzer DT, Kort HW, Day RW, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation. Sep 24 2002;106(12 Suppl 1):I76–I81
  107. Lock JE, Einzig S, Bass JL, Moller JH. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol. 1982;3:41–46
  108. Dammann JF, MCeachen JA, Thompson WM, Smith R, Muller WH. The regression of pulmonary vascular disease after the creation of pulmonary stenosis. J Urol Nephrol (Paris). Dec 1961;42:722–734
  109. Wagenvoort CA, Wagenvoort N, Draulans-Noë Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg. 1984;87:876–886
  110. Azzolina G. Discussion of high pressure, high resistance ventricular septal defect surgical results of closure through right atrium. J Thorac Cardiovasc Surg. 1971;12:37
  111. Batista RJV, Santos JLV, Takeshita N, et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol. 1997;68:279–280
  112. Novick WM, Gurbuz AT, Watson DC, et al. Double patch closure of ventricular septal defect with increased pulmonary vascular resistance. Ann Thorac Surg. 1998;66:1533–1538
  113. Novick WM, Sandoval N, Lazorhysynets VV, et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. discussion -8 Ann Thorac Surg. Jan 2005;79(1):21–28
  114. Sandoval J, Alvarado P, Martinez-Guerra ML, et al. Effect of body position changes on pulmonary gas exchange in Eisenmenger's syndrome. Am J Respir Crit Care Med. Apr 1999;159(4 Pt 1):1070–1073
  115. Sandoval J, Aguire JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164:1682–1687
  116. Kulik TJ. Inhaled nitric oxide in the management of congenital heart disease. Curr Opin Cardiol. Jan 1996;11(1):75–80
  117. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81
  118. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. Jun 14 2005;111(23):3105–3111
  119. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. Jun 16 2004;43(12 Suppl S):40S–47S
  120. Wong CK, Yeung DW, Lau CP, Cheng CH, Leung WH. Improvement of exercise capacity after nifedipine in patients with Eisenmenger syndrome complicating ventricular septal defect. Clin Cardiol. Dec 1991;14(12):957–961
  121. Wimmer M, Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc Drugs Ther. Apr 1992;6(2):183–186
  122. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–1865
  123. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. Mar 1 2003;91(5):632–635
  124. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. Jul 4 2006;114(1):48–54
  125. D'Alto M, Vizza CD, Romeo E, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart (British Cardiac Society). May 2007;93(5):621–625
  126. Gatzoulis MA, Beghetti M, Galie N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. Jun 23 2008;127(1):27–32
  127. van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J. Oct 2007;154(4):776–782
  128. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart (British Cardiac Society). Nov 2005;91(11):1447–1452
  129. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart (British Cardiac Society). Mar 2007;93(3):350–354
  130. Sitbon O, Beghetti M, Petit J, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest. Sep 2006;36(Suppl 3):25–31
  131. Kourouklis S, Christopoulos A, Liagkas K, Paradellis G, Kyriakides ZS. Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension. Eur J Clin Invest. Sep 2006;36(Suppl 3):39–43
  132. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart (British Cardiac Society). Aug 2007;93(8):974–976
  133. Benza RL, Rayburn BK, Tallaj JA, et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest. Apr 2006;129(4):1009–1015
  134. Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol. Jul 15 2004;94(2):261–263
  135. Durongpisitkul K, Jakrapanichakul D, Sompradikul S. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease. Journal of the Medical Association of Thailand=Chotmaihet thangphaet. Feb 2008;91(2):196–202
  136. Kotlyar E, Sy R, Keogh AM, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young. Jun 2006;16(3):268–274
  137. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J. Oct 2005;150(4):716
  138. Duffels MG, Vis JC, van Loon RL, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option?. Int J Cardiol. Jun 23 2008;
  139. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2–11years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res. Aug 2008;64(2):200–204
  140. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697–704
  141. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441–447
  142. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. May 16 2006;47(10):2049–2056
  143. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. Oct 2008;134(4):775–782
  144. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart (British Cardiac Society). May 2006;92(5):664–670
  145. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation. 2002;105:2398–2403
  146. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;108:2066–2069
  147. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. Sep 3 2007;120(3):301–305
  148. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. Jun 13 2005;
  149. Wort SJ. Sildenafil in Eisenmenger syndrome: safety first. Int J Cardiol. Sep 3 2007;120(3):314–316

PII: S1058-9813(09)00028-9

doi: 10.1016/j.ppedcard.2009.09.005

Progress in Pediatric Cardiology
Volume 27, Issue 1 , Pages 25-33 , December 2009

Article Tools

* Image Usage & Resolution